Evaluación histológica del daño renal producido por los inhibidores del punto de control inmunitario

  1. Revuelta, Sara 1
  2. Tascón, Javier 1
  3. Vicente-Vicente, Laura 1
  4. Casanova, Alfredo G. 1
  5. Morales, Ana I. 1
  6. Prieto, Marta 1
  1. 1 Universidad de Salamanca
    info

    Universidad de Salamanca

    Salamanca, España

    ROR https://ror.org/02f40zc51

Journal:
Farmajournal

ISSN: 2445-1355

Year of publication: 2022

Volume: 7

Issue: 2

Pages: 53-65

Type: Article

DOI: 10.14201/FJ2022725365 DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Farmajournal

Abstract

Immune checkpoint inhibitors (ICI) constitute the most relevant immunotherapeutic group in the oncology field, but they are not exempt from adverse effects. Renal lesions, although rare, worsen the prognosis. Currently there are combinations of immunotherapy and chemotherapy that improve efficacy but increase the risk of nephrotoxic side effects. The objective was the histological evaluation of renal damage associated with ICI anti-CTLA-4 and anti-PD-1 in combination with cisplatin. An experimental model was designed in C57BL/6 mice treated with the combined therapy of cisplatin (10 mg/kg, single dose) with anti-CTLA-4 or with anti-PD-1 (both 10 or 15 mg/kg/day, for 6 days). Groups with drug monotherapies and a control group were included. Histological kidney damage assessment was performed blindly following a scale-based tissue injury quantification protocol. The data were analyzed with the statistical program IBM SPSS Statistics. The results showed renal tubular damage, more pronounced in the outer cortex, associated with cisplatin treatment, while there were no structural alterations in monotherapy with ICI. Co-treatment potentiated renal structural damage from cisplatin. This potentiation was more evident in the corticomedullary region, so it seems that the drug combination causes a deeper injury in the kidney.

Bibliographic References

  • Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways similarities, differences, and implications of their inhibition. J. Clin. Oncol. 2016; 39(1):98-106.
  • Cancer.Net [Internet]. EE. UU.: American Society of Clinical Oncology; 2020 [actualizado may 2020; citado 5 abr 2022]. Disponible en: https://www.cancer.net/es/desplazarse-por-atencion-del-cáncer/cómo-se-trata-el-cáncer/inmunoterapia/qué-es-la-inmunoterapia
  • Cancer Research UK [Internet]. Londres: Cancer Research UK; 2021 [actualizado 20 ene 2021; citado 5 abr 2022]. Disponible en: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/immunotherapy/what-is-immunotherapy
  • De Francisco ALM, Macía M, Alonso F, García P, Gutiérrez E, Quintana LF et al. Onco-Nefrología: cáncer, quimioterapia y riñón. Nefrología. 2019; 39(5):473-481.
  • Dumoulin DW, Visser S, Cornelissen R, van Gelder T, Vansteenkiste J, von der Thusen J et al. Renal Toxicity From Pemetrexed and Pembrolizumab in the Era of Combination Therapy in Patients With Metastatic Nonsquamous Cell NSCLC. J Thorac Oncol. 2020; 15(9):1472-1483.
  • El Rassy E, Bakouny Z, Yared F, Chelala DN, El Karak F, Ghosn M. The nephrotoxicity of immune checkpoint inhibitor-based combinations. Eur J Cancer. 2018; 103:274-278.
  • Perazella MA, Shirali AC. Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do? Kidney Int. 2020; 97(1):62-74.
  • Prost, DM, Cinat, G. Manejo de toxicidades por inmunoterapia. Puesta al día. 2017; 22:46-51.
  • Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017; 5(1):95.
  • Spielbauer K, Cunningham L, Schmitt, N. PD-1 Inhibition Minimally Affects Cisplatin-Induced Toxicities in a Murine Model. Sage Journals. 2018; 159(2):343-346.
  • Spiers L, Coupe N, Payne M. Toxicities associated with checkpoint inhibitors—an overview. Rheumatology. 2019; 58(7):7-16.
  • Who.int [Internet]. World Health Organization; 2022 [actualizado 2 feb 2022; citado 5 abr 2022]. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/cancer
Data source: Dialnet